Profile
General Information
Asacol (mesalamine) was approved by the Food and Drug Administration in August 1997. Asacol tablets are indicated for the treatment of mildly to moderately active ulcerative colitis and for the maintenance of remission of ulcerative colitis.
Side Effects
Side effects include headaches, abdominal pain, eructation, and nausea.
Approval Date: 1997-08-01
Company Name: Procter & Gamble